Radiotherapy for Rectal Cancer and Radiation-Induced Malignancies from Epidemiological and Dosimetric Data

被引:0
作者
Kachris, Stefanos [1 ]
Mazonakis, Michalis [2 ]
机构
[1] Univ Hosp Iraklion, Dept Radiat Oncol, Iraklion 71110, Greece
[2] Univ Crete, Fac Med, Dept Med Phys, Iraklion 71003, Greece
来源
APPLIED SCIENCES-BASEL | 2024年 / 14卷 / 24期
关键词
rectal cancer; radiotherapy; second malignancies; epidemiological data; dosimetry; INTENSITY-MODULATED RADIOTHERAPY; TOTAL MESORECTAL EXCISION; OUT-OF-FIELD; 2ND PRIMARY CANCERS; PREOPERATIVE RADIOTHERAPY; RANDOMIZED-TRIAL; ADJUVANT CHEMOTHERAPY; SECONDARY-CANCER; PHASE-II; POSTOPERATIVE CHEMORADIOTHERAPY;
D O I
10.3390/app142412063
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Preoperative or postoperative radiation therapy is broadly employed in patients with rectal carcinoma. Radiotherapy directs high-energy beams of ionizing radiation toward the tumor area to destroy cancer cells. High radiation doses are needed for cell killing. The radiation exposure of the healthy tissues/organs may lead to carcinogenesis. This study describes the evolving role of radiotherapy in rectal cancer management. The present report also reviews epidemiological and dosimetric studies related to the radiation-induced second malignancies from pelvic radiotherapy. Some epidemiological studies have concluded that the second-cancer risk in patients subjected to radiation therapy does not increase compared to unexposed rectal cancer patients. Other researchers found an elevated or a marginally increased probability for second-cancer induction. Dosimetric studies reported cancer risk estimates for critical organs or tissues in the near and far periphery of the treatment volume. Useful information about the effect of the treatment parameters such as the irradiation technique, photon beam energy, and fractionation schedule on the organ-specific second-cancer risk was derived from the dose data analysis. The knowledge of these effects is needed for the selection of the optimal treatment parameters enabling a reduction in the resultant risk of carcinogenesis.
引用
收藏
页数:14
相关论文
共 80 条
[1]  
Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin, 74, pp. 229-263, (2024)
[2]  
Siegel R.L., Wagle N.S., Cercek A., Smith R.A., Jemal A., Colorectal cancer statistics, 2023, CA Cancer J. Clin, 73, pp. 233-254, (2023)
[3]  
NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer, Version 4, (2024)
[4]  
Scott A.J., Kennedy E.B., Berlin J., Brown G., Ghalabi M., Cho M.T., Cusnir M., Dorth J., George M., Kachnic L.A., Et al., Management of locally advanced rectal cancer: ASCO guideline, J. Clin. Oncol, 42, pp. 3355-3375, (2024)
[5]  
Fadel M.G., Ahmed M., Malietzis G., Pellino G., Rasheed S., Brown G., Tekkis P., Kontovounisios C., Oncological outcomes of multimodality treatment for patients undergoing surgery for locally recurrent rectal cancer: A systematic review, Cancer Treat. Rev, 109, (2022)
[6]  
De Nes L.C.E., Heil T.C., Verhoeven R.H.A., Lemmens V.E.P.P., Rutten H.J., De Wilt J.H.W., Vissers P.A.J., Impact of age on multimodality treatment and survival in locally advanced rectal cancer patients, Cancers, 14, (2022)
[7]  
Palta M., Czito B.G., Willett C.G., Cancer of the colon and rectum, Principles and Practice of Radiation Oncology, pp. 1481-1501, (2019)
[8]  
Tseng M., Soon Y.Y., Vellayappan B., Ho F., Tey F., Radiation therapy for rectal cancer, J. Gastrointest. Oncol, 10, pp. 1238-1250, (2019)
[9]  
Hanna C.R., Slevin F., Appelt A., Beavon M., Adams R., Arthur C., Beasley M., Duffton A., Gilbert A., Collins S., Et al., Intensity modulated radiotherapy for rectal cancer in the UK in 2020, Clin. Oncol, 33, pp. 214-233, (2021)
[10]  
Hall E.J., Giaccia A.J., Radiobiology for the Radiologist, (2012)